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Background: Mounting clinical and experimental data suggest that the migration of tumor cells into lymph nodes
is greatly facilitated by lymphangiogenesis. Vascular endothelial growth factor (VEGF)-C and D have been identified
as lymphangiogenic growth factors and play an important role in tumor lymphangiogenesis. The purpose of this
study was to investigate the location of lymphangiogenesis driven by tumor-derived VEGF-C/D in breast cancer,
and to determine the role of intratumoral and peritumoral lymphatic vessel density (LVD) in lymphangiogenesis in
breast cancer.
Methods: The expression levels of VEGF-C/D were determined by immunohistochemistry, and intratumoral LVD
and peritumoral LVD were assessed using immunohistochemistry and the D2-40 antibody in 73 patients with
primary breast cancer. The associations of intratumoral LVD and peritumoral LVD with VEGF-C/D expression,
clinicopathological features and prognosis were assessed.
Results: VEGF-C and D expression were significantly higher in breast cancer than benign disease (P< 0.01). VEGF-C
(P< 0.001) and VEGF-D (P= 0.005) expression were significantly associated with peritumoral LVD, but not
intratumoral LVD. Intratumoral LVD was associated with tumor size (P= 0.01). Peritumoral LVD was significantly
associated with lymph node metastasis (LNM; P= 0.005), lymphatic vessel invasion (LVI; P= 0.017) and late tumor,
node, metastasis (TNM) stage (P= 0.011). Moreover, peritumoral LVD was an independent risk factor for axillary
lymph node metastasis, overall survival and disease-free survival in multivariate analysis.
Conclusions: This study suggests that tumor-derived VEGF-C/D induce peritumoral lymphangiogenesis, which may
be one mechanism that leads to lymphatic invasion and metastatic spread. Peritumoral LVD has potential as an
independent prognostic factor in breast cancer patients.
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Breast carcinoma is the most common malignant tumor
in females, and the incidence of this disease has signifi-
cantly increased from one per twenty women in the
1960s to one in eight today [1]. Lymph node status is
the most important prognostic factor in patients with* Correspondence: lcy0508@yahoo.com.cn
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reproduction in any medium, provided the orbreast cancer. Lymphatic metastasis was previously
thought to be a passive process, by which detached
tumor cells enter lymph nodes in the vicinity of a pri-
mary tumor via pre-existing lymphatic vessels [2]. Lym-
phangiogenesis is the formation of new lymphatic
vessels, and during the last several years, lymphangio-
genesis driven by tumor-derived lymphangiogenic
growth factors has been firmly established as a novel
mechanism for cancer progression.
Lymphatic metastasis represents a series of sequential
processes that include the dissemination and invasion oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing stromal tissue, penetration of the tumor cells
across the lymphatic walls, implantation in the regional
lymph nodes, and extravasation and proliferation in the
parenchyma of target organs [3]. Two members of the
vascular endothelial growth factor family, VEGF-C and
VEGF-D, have been defined as lymphangiogenic growth
factors and play an important role in tumor lymphangio-
genesis via activation of the VEGF receptor (VEGFR)-3,
which is expressed in lymphatic endothelial cells. In ex-
perimental tumor models, expression of VEGF-C and
VEGF-D has been shown to induce lymphangiogenesis
and correlate with lymphatic invasion and nodal metas-
tasis [4,5]. Elevated expression of VEGF-C has been
reported in 30 to 40 percent of breast cancers, and is
associated with a higher incidence of lymphatic vessel
invasion, lymph node metastasis and poorer disease-free
survival (DFS) [6,7]. VEGF-D is involved in the lymph-
atic spread of breast cancer cells and is an independent
prognostic factor for poor outcome in breast cancer [8].
The intratumoral and peritumoral lymphatic systems
play distinct biological roles in the behavior and progno-
sis of tumors. Intratumoral lymphatic endothelial cells
are capable of proliferation, suggestive of de novo lym-
phangiogenesis. A correlation between intratumoral
lymphatic vessel density (LVD) and nodal metastasis has
been reported in some solid tumors [9,10], but not in
other studies where nonfunctional intratumoralTable 1 Association of P-LVD and I-LVD with the clinicopatho
Factor Cases (N) I- LVD (mean± SD)
Age
>50 46 5.41 ± 2.09
≤50 27 5.59 ± 1.99
Grade
I / II 55 5.56 ± 2.05
III 18 5.23 ± 2.02
Size
≤3 cm 33 6.12 ± 1.95
>3 cm 40 4.94 ± 1.98
LNM
Negative 34 5.58 ± 1.92
Positive 39 5.38 ± 2.15
LVI
Negative 48 5.57 ± 2.11
Positive 25 5.29 ± 1.96
TNM
I - II 41 5.34 ± 2.05
III 32 5.62 ± 2.04
I-LVD, intratumoral lymphatic vessel density; LNM, lymph node metastasis; LVI, lymp
node,metastasis stage.lymphatics were quantified using dye uptake measure-
ments [11]. Tumor-derived VEGF-C and D can induce
either intratumoral or peritumoral lymphangiogenesis;
however, the relative importance of the intratumoral
lymphatic vessels and peritumoral lymphatic vessels in
metastasis of breast cancer cells to the draining lymph
nodes remains unclear.
Therefore, in the present study we quantified the
intratumoral LVD and peritumoral LVD in primary inva-
sive ductal breast carcinoma using D2-40 immunohisto-
chemistry, and correlated these results with VEGF-C and




Paraffin-embedded specimens were obtained from 73
patients aged 29 to 75 years (mean, 53.79 ± 14.09 years)
who had primary invasive ductal breast cancer and
received surgical treatment between January 2005 and
December 2006 at the Department of Breast Surgery,
Wuhu Second People’s Hospital, Wannan Medical College,
China. The study was carried out with the approval
of the Research Ethics Committee of Wuhu Second
People’s Hospital affiliated to Wannan Medical College.
Full clinical and pathological data was collected for all 73
patients. The clinicopathologic features of the patients
were summarized in Table 1. No patients had distantlogical features of 73 primary breast cancer patients
P-value P-LVD (mean± SD) P-value
0.87 8.63 ± 2.92 0.62
9.02 ± 3.90
0.58 8.17 ± 2.88 0.47
8.97 ± 3.42
0.01 8.24 ± 3.47 0.24
9.22 ± 3.12
0.74 7.57 ± 3.10 0.005
9.82 ± 3.13
0.38 8.04 ± 2.89 0.017
10.19 ± 3.61
0.72 7.92 ± 3.44 0.011
9.69 ± 2.91
hatic vessel invasion; P-LVD, peritumoral lymphatic vessel density; TNM, tumor,
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therapy before surgery. Benign tissues from 20 patients with
mammary fibroma were selected as controls.
All of the breast cancer patients received post-
operative adjuvant therapy consisting of combination
chemotherapy and hormone treatment, and were fol-
lowed up clinically for at least 5 years after surgery. The
average follow-up time was 55 months (range 8 to
73 months). Follow-up examinations included a physical
examination, X-ray, ultrasound exam and CT scan. Re-
currence was determined by clinical and radiological
examinations or histological confirmation.
Immunohistochemical staining
Single D2-40, VEGF-C or VEGF-D immunohistochemis-
try was performed on formalin-fixed, paraffin-embedded
sections. The sections (4 μm) were cleared, treated with
0.3% H2O2 for 10 minutes at room temperature to in-
hibit endogenous peroxidase activity, and then placed in
0.01 mM/L sodium citrate (pH 6.0) and heated in a
microwave oven for antigen retrieval. The slides were
incubated with mouse monoclonal VEGF-C primary
antibody (1:100, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), mouse monoclonal VEGF-D primary anti-
body (1:100, Santa Cruz Biotechnology), or D2-40 mouse
monoclonal antibody (1:25, Signet Laboratories, Dedham,
MA, USA) at 4°C overnight in a humidified atmosphere,
rinsed three times in 0.1 mM/L PBS for 2 minutes, incu-
bated for 30 minutes at room temperature with goat anti-
mouse horseradish peroxidase (Boster, Wuhan, China)
and staining was developed using 3′3-diaminobenzidine.
The primary antibodies were replaced with non-specific
rabbit immunoglobulin G (IgG) to prepare the negative
control slides.
The immunohistochemical staining results were inter-
preted by two experienced pathologists and the mean
staining density was determined using ImagePro Plus 6.0
(ImagePro, Bethesda, MD, USA). VEGF-C and VEGF-D
staining were semi-quantitatively assessed by combining
the immunohistochemical staining intensity [none (0),
weak (1), moderate (2) or strong (3)] with the percentage
of tumor cells stained [0 (0%), 1 (1 to 10%), 2 (11 to
49%) or 3 (50 to 100%)]. The raw data were then con-
verted to an Immunoreactive Score (IRS) by adding the
scores for the staining intensity and percentage of tumor
cells stained [12]. An IRS of 0 to 2 was considered ‘-’
(negative), 3 as ‘+’, 4 to 5 as ‘++’, 6 as ‘+++’ and 7 as ‘++++’.
Consensus opinions were used to assign final IRS scores
to disputed cases before data analysis.
Assessment of LVD
Intratumoral and peritumoral LVD were determined by
the hotspot method as previously described [13]. Briefly,
intratumoral LVD (located at center of the tumor) andperitumoral LVD (located in the peripheral tissue within
2 mm of the tumor, adjacent to the invasive front) were
assessed. In all cases, LVD was independently deter-
mined by two pathologists, who counted the number of
D2-40-positive vessels in five high-power fields of view
within the selected areas. Mean values were recorded for
these counts. Lymphatic vessel invasion (LVI) was
defined as the presence of at least one tumor cell cluster
within the D2-40-positive vessels [14]. High intratumoral
and peritumoral LVD were defined as LVD values higher
than the respective median LVD values for all patients.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 (SPSS,
Chicago, IL, USA). The Mann -Whitney U test or ana-
lysis of variance (ANOVA) were used to compare intra-
tumoral and peritumoral LVD values, according to the
clinicopathological variables. Multivariate analysis of risk
factors for lymph node metastasis was performed using
multivariate logistic regression analysis. Overall survival
(OS) and disease-free survival (DFS) curves were plotted
using the Kaplan - Meier method and compared using
the log-rank test. A multivariate model was generated
using Cox stepwise regression analysis and used to
evaluate the significance of the independent associations
between the covariates and DFS and/or OS. All statis-
tical tests were two sided and significance was defined as
P < 0.05.
Results
VEGF-C and VEGF-D expression in human breast cancer
VEGF-C and VEGF-D immunoreactivity were both
observed as positive cytoplasmic staining in breast can-
cer cells (Figure 1). VEGF-C expression was not detected
in the breast cancer tissues of 11/73 patients (15.1%);
17/73 (23.3%) of the patients were ‘+’, 26/73 (35.6%) were
‘++’, 12/73 (16.4%) were ‘+++’ and 7/73 (9.6%) were ‘++++’
for VEGF-C. VEGF-D expression was not detected in 18/
73 patients (24.7%); 20/73 (27.4%) of the patients were ‘+’,
21/73 (28.8%) were ‘++’, 9/73 (12.3%) were ‘+++’ and 5/73
(6.8%) were ‘++++’ for VEGF-D. Weak VEGF-C and D
immunoreactivity was observed in 5/20 (25%) and 3/20
(15%) of the mammary fibroma samples, respectively; the
remainder of the control samples did not express VEGF-
C/D. The expression levels of VEGF-C and D were sig-
nificantly higher in primary breast carcinoma than the
control fibroma tissues (P< 0.01; Table 2.)
Characteristics of intratumoral lymphatics and
peritumoral lymphatics in breast cancer
D2-40-stained lymphatic vessels were unevenly distribu-
ted throughout the breast tumors. Lymph vessels within
the tumor mass were generally small, irregular and col-
lapsed (Figure 2A). The lymph vessels in the peritumoral
Figure 1 Immunohistochemical analysis of VEGF-C and VEGF-D expression in primary breast carcinoma. (A) Histopathology by
hematoxylin-eosin staining of breast cancer; (B) Strong expression of VEGF-C and (D) negative control in breast cancer; (C) Strong expression of
VEGF-D and (E) negative control in breast cancer. Diffuse, strong positive VEGF-C (B) and VEGF-D (C) immunostaining was mainly observed in the
cytoplasm of breast cancer cells (magnification × 400). VEGF-C/D, vascular endothelial growth factor C /D.
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As expected, D2-40 immunostaining highlighted the
presence of lymphatic invasion (Figure 2C), which is
usually present at the periphery of tumors. No signifi-
cant difference was observed between the intratumoral
LVD of breast carcinoma and the LVD of control tissues
(5.47 ±2.03 vs. 5.25 ± 1.73, P > 0.05). However, the peritu-
moral LVD (8.77 ± 3.30) was significantly higher than the
intratumoral LVD and LVD of control tissues (P < 0.05).Relationship of intratumoral LVD and peritumoral LVD
with VEGF-C/D expression and clinicopathological
features
Significant correlations were observed between the ex-
pression of VEGF-C/D and peritumoral LVD in pri-
mary breast carcinoma. Specifically, peritumoral LVD
increased as VEGF-C/D expression increased (P < 0.01).Table 2 Association of VEGF-C and VEGF-D expression with P
Cases (N) I- LVD (mean± S
VEGF-C Negative 11 5.17 ± 2.23
+ 17 5.72 ± 2.02
++ 26 5.41 ± 1.94
+++ 12 5.46 ± 2.19
++++ 7 5.59 ± 2.44
VEGF-D Negative 18 5.19 ± 2.25
+ 20 5.35 ± 1.81
++ 21 5.53 ± 1.86
+++ 9 5.81 ± 2.53
++++ 5 6.16 ± 2.47
I-LVD, intratumoral lymphatic vessel density; P-LVD, peritumoral lymphatic vessel de
variance.No similar relationships between VEGF-C/D and intra-
tumoral LVD were observed (Table 2).
The association of intratumoral LVD and peritumoral
LVD with the clinicopathological features of breast can-
cer are shown in Table 1. Intratumoral LVD and peritu-
moral LVD did not correlate with patient age or tumor
grade; however, intratumoral LVD correlated with tumor
size (P= 0.01) and peritumoral LVD correlated signifi-
cantly with lymph node metastasis (P= 0.005), LVI
(P= 0.017) and TNM stage (P= 0.011; Table. 1).
Predictive value of intratumoral LVD and peritumoral LVD
for axillary lymph node metastasis
Multivariate logistic regression analysis indicated that
VEGF-C expression, peritumoral LVD and the presence
of LVI were significantly associated with axillary lymph
node metastasis (P= 0.027, P= 0.006 and P= 0.019, re-
spectively). Intratumoral LVD and VEGF-D expression-LVD and I-LVD in breast cancer
D) P-valuea P-LVD (mean± SD) P-valuea










nsity; VEGF-C/D, vascular endothelial growth factor C /D; aOne-way analysis of
Figure 2 Immunohistochemical analysis of lymphatic vessels in primary breast carcinoma. (A) Intense, specific D2-40 immunoreactivity
was only observed in lymphatic endothelial cells. The intratumoral lymphatic vessels are small, irregular and collapsed (arrow). (B) The peritumoral
lymphatic vessels located at the invasive edge of tumors are frequent, often large and dilated (arrow); magnification× 200.(C)
Immunohistochemical visualization of invading breast cancer cells in the lymphatic vessels of the peritumoral region of a primary breast
carcinoma. The black arrow indicates lymphatic vessel invasion (LVI); magnification× 200.
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sis in breast cancer (Table 3).
Survival analysis
The 5-year DFS rate for the 73 patients was 57.53% (42/
73), and the 5-year OS rate was 65.75% (48/73). We
divided the 73 patients into two groups, using the me-
dian intratumoral LVD and peritumoral LVD values (6.0
and 9.0, respectively) as cut-off points. In univariate sur-
vival analysis, intratumoral LVD demonstrated a non-
significant trend towards OS (P= 0.417; Figure 3A) and
DFS (P= 0.274; Figure 3B). However, high peritumoral
LVD was significantly associated with poorer OS
(P= 0.007; Figure 3C) and DFS (P= 0.004; Figure 3D).
Furthermore, multivariate regression analysis indicated
that peritumoral LVD was an independent prognostic
factor for both OS (P <0.001) and DFS (P= 0.001).
Moreover, the presence of LNM and TNM stage alsoTable 3 Multivariate logistic regression analysis of the
factors affecting axillary lymph node metastasis in
primary breast carcinoma
P-value Odds ratio 95% CI
P-LVD 0.006 2.255 1.269-4.008
I-LVD 0.168 0.709 0.434-1.156
VEGF-C 0.027 11.837 1.327-45.584
VEGF-D 0.147 0.249 0.038-1.627
LVI 0.019 4.167 2.755-15.363
CI, confidence interval; I-LVD, intratumoral lymphatic vessel density; LVI,
lymphatic vessel invasion; P-LVD, peritumoral lymphatic vessel density; VEGF-
C/D, vascular endothelial growth factor C /D.served as independent predictors for both OS and DFS
(LNM: P= 0.037 and 0.040; TNM stage, P= 0.035 and
0.006, respectively). However, no significant correlations
were observed between intratumoral LVD, VEGF-C,
VEGF-D or LVI and any survival outcome (Table 4).
Discussion
Metastatic spread of tumor cells is responsible for the
majority of cancer-related deaths. In similar manner to
other carcinomas, breast cancer has a predilection to
initially metastasize to the regional lymph nodes [15],
most commonly via the lymphatic system [16]. Lym-
phangiogenesis is considered to be a key process dur-
ing lymphatic metastasis [2]; however, the role of
lymphangiogenesis in promoting the metastatic spread
of tumor cells via lymphatic vessels has received little
attention in the last decade. This has been in part due
to the difficulty of studying lymphatic vessels, due to
their morphology, and a lack of lymphatic-specific
markers [17]. Recently, the D2-40 antibody has been
shown to specifically recognize the glomerular podo-
cyte membrane protein Podoplanin, and is a very sen-
sitive and specific marker for lymphatic endothelium
in most tissues, especially breast cancer [18]. In ‘The
First International Consensus on The Methodology of
Lymphangiogenesis Quantification in Solid Human
Tumors’ [19], Podoplanin was considered to be the
most reliable marker of lymphatic vessels currently
available. In this study, D2-40 produced strong and
specific lymphatic vessel immunoreactivity in breast
cancer. In agreement with previous reports [20], the
Figure 3 Kaplan-Meier disease-related overall survival (A and C) and disease-free survival (B and D) curves; stratified by low versus
high intratumoral LVD (A and B) and low versus high peritumoral LVD (C and D) in invasive ductal breast carcinoma. The median LVD
values were used as cutoff values. LVD, lymphatic vessel density.
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usually had an irregular shape and thin-walled lumen
devoid of red blood cells. The intratumoral vessels
were generally collapsed, whereas the peritumoral ves-
sels were wider, with more dilated lumina, and tumor
emboli were more frequently observed within the peri-
tumoral lymphatics.
This study aimed to clarify the location of VEGF-C/D-
induced lymphangiogenesis and investigate the role of
intratumoral and peritumoral lymphatic vessels in
lymph node metastasis and the outcome of patientsTable 4 Cox regression analysis of the independent
factors affecting overall survival and disease-free survival
in primary breast carcinoma
Overall survival Disease-free survival
OR (95% CI) P-value OR (95% CI) P-value
P-LVD 3.077 (2.086-4.539) 0.000 2.245 (1.602-3.144) 0.001
I-LVD 0.927 (0.709-1.212) 0.579 1.086 (0.830-1.422) 0.547
VEGF-C 0.637 (0.225-1.804) 0.396 0.432 (0.169-1.103) 0.079
VEGF-D 1.900 (0.690-5.230) 0.214 2.025 (0.842-4.872) 0.115
LNM 3.564 (1.081-11.749) 0.037 13.333 (1.125-68.667) 0.040
LVI 1.218 (0.457-3.250) 0.693 1.421 (0.566-3.567) 0.454
TNM stage 4.464 (1.111-18.182) 0.035 5.917 (1.681-20.833) 0.006
I-LVD, intratumoral lymphatic vessel density; LNM, lymph node metastasis; LVI,
lymphatic vessel invasion; P-LVD, peritumoral lymphatic vessel density; TNM,
tumor,node,metastasis stage.with breast cancer. Lymphangiogenesis is controlled by
a complex network of growth factors, cytokines and
chemokines, and actively contributes to tumor metas-
tasis [21]. Skobe et al. first demonstrated that VEGF-C
induced lymphangiogenesis and promoted metastasis
in animal studies [22]. Over-expression of VEGF-C
triggers lymphangiogenesis and is associated with a
higher risk of cervical lymph node metastasis in oral
squamous cell carcinoma [23]. Stacker et al. described
the induction of lymphangiogenesis by VEGF-D-over-
expressing tumor cells in the skin of severe combined
immunodeficient (SCID) mice [24]. Similar to a previ-
ous report [6], our results demonstrated that both
VEGF-C and VEGF-D are expressed at significantly
higher levels in breast cancer than in benign mammary
lesions. However, previous studies have not evaluated
the relationship between LVD and VEGF-C/D in differ-
ent regions of tumors. We observed that peritumoral
LVD was significantly higher than intratumoral LVD
and the LVD of control tissues. Additionally, the peri-
tumoral LVD was closely related to expression of
VEGF-C and VEGF-D; however, intratumoral LVD was
not related to VEGF-C/D. These results suggest that
tumor-derived VEGF-C/D induce lymphangiogenesis
around tumors, but not within breast tumors.
Considerable debate remains regarding the role of
intratumoral versus peritumoral lymphatic vessels in the
pathology of primary human tumors. Proliferating
Zhao et al. World Journal of Surgical Oncology 2012, 10:165 Page 7 of 9
http://www.wjso.com/content/10/1/165intratumoral lymphatics have been observed in tumor
xenotransplants and in slowly growing, chemically-
induced, orthotopic squamous cell carcinomas (SCC) in
mice, and also in primary human skin malignant mela-
nomas that metastasized to the lymph nodes [25,26]. In
recent years, several studies have associated intratumoral
LVD with tumor lymph node metastasis in pancreatic
endocrine tumors [27], head and neck squamous cell
carcinoma [9] and papillary thyroid carcinoma [28].
Moreover, Skobe et al. also suggested that over-
expression of VEGF-C in breast cancer cells potently
increased intratumoral lymphangiogenesis, which signifi-
cantly enhanced metastasis to the regional lymph nodes
and lungs [22]. However, using an experimental system,
Padera et al. demonstrated the occurrence of metastatic
spread in the absence of detectable intratumoral lymph-
atic vessels, and proposed that the functional lymphatics
at the tumor margin are sufficient for the promotion of
metastasis, as they offer a large area for tumor cell es-
cape [11]. A recent study in an experimental model of
prostate cancer also observed efficient metastasis to the
lymph nodes in the absence of intratumoral lymphatics
[29]. Bono et al. reported that peritumoral lymphatics
were far more frequent than intratumoral vessels, and
the extent of peritumoral lymphatic vessels correlated
with nodal metastasis [30]. Most of the available data
indicates a strong correlation between peritumoral
lymphangiogenesis and tumor aggressiveness. Our
results are in agreement with the latter studies; we
observed that the density of lymphatic vessels was usu-
ally greater at the tumor periphery than intratumorally,
and that a high peritumoral LVD, not intratumoral
LVD, was associated with more aggressive behavior in
breast carcinoma.
We also investigated the relationship between intra-
tumoral LVD, peritumoral LVD and clinicopathological
features in breast cancer. Intratumoral LVD was sig-
nificantly related to the primary tumor size, with larger
tumors having a lower intratumoral LVD. One possi-
bility for this observation is that the tumor tissue lym-
phatics are destroyed by invading tumor cells or high
interstitial fluid pressure due to the expanding tumor
mass [3]. More importantly, there was a significant
correlation between peritumoral LVD and lymphatic
vessel invasion, lymph node metastasis and TNM clin-
ical stage, indicating that VEGF-C/D-induced peritu-
moral lymphangiogenesis leads to lymphatic invasion
and lymph node metastasis. The contradictory results
on the role of intratumoral-lymphatic vessels and
peritumoral-lymphatic vessels in tumors reflect the fact
that tumor lymphangiogenesis and lymphatic metasta-
sis are complex mechanisms, which can differ signifi-
cantly in different tumor types or in tumors at
different anatomic locations [31].It was also important to examine whether intratumoral
LVD or peritumoral LVD had any prognostic value in
breast carcinoma. Peritumoral LVD and intratumoral
LVD are risk factors for lymph node metastasis in early
gastric cancer [32]. In this study, multivariate analysis
indicated that only peritumoral LVD was an independent
predictor of axillary lymph node metastasis. No correla-
tions were observed between intratumoral LVD and pa-
tient outcome; however, increased peritumoral LVD was
associated with poorer DFS and OS. Multivariate ana-
lysis also indicated that increased peritumoral LVD was
a prognostic factor for DFS and OS in breast cancer.
These findings are in agreement with other studies, as
the LVD in the periphery of tumors correlates with
poorer outcomes in lung [33], colorectal [34] and pros-
tate cancer [35]. This evidence demonstrates that peritu-
moral lymphangiogenesis plays an important role in
lymphatic metastasis and tumor progression, and that
peritumoral lymphangiogenesis is an independent pre-
dictor of lymph node metastasis and prognostic factor in
breast carcinoma. Most solid tumors metastasize via
lymphatic invasion; therefore LNM is an important
prognostic factor [3], and as expected, LNM and TNM
were also prognostic factors for DFS and OS in breast
cancer.
In this study, lymphatic vessel invasion (LVI) of the
tumor was not associated with either overall survival
rates or disease-free survival in multivariate analysis, but
was weakly correlated with axillary LNM. This discrep-
ancy could be explained in several ways. Firstly, the
histopathological detection of LVI may have under-
represented the true number of involved lymphatic ves-
sels after the selection of tumor tissue regions. Secondly,
the involvement of lymphatic vessels by tumor does not
necessarily mean that lymph nodes have been affected,
which may result in some of patients classified as having
LVI, but with a lower TNM score than those with
proven lymph node involvement. Consequently, LVI
could be perceived as a less accurate marker of progno-
sis than lymph node involvement and TNM stage, which
is borne out in our results, as it does not reflect the de-
gree of distant spread. The latter may be dependent on
the ability of tumor cells to migrate, and would therefore
mean that LVI was not a direct marker of survival. It is
however an interesting parameter that should be taken
into account in the grading of tumors.
In summary, our results suggest that high levels of
VEGF-C/D expression by breast tumor cells may in-
duce lymphangiogenesis in the peritumoral region and
contribute to a high peritumoral LVD, leading to
increased aggressiveness, lymphatic invasion, metastatic
spread and a poorer prognosis. Inhibiting the expres-
sion, or blocking the function, of VEGF-C/D to control
peritumoral lymphangiogenesis is expected to lead to
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treatment and management of breast cancer; however,
further characterization of the molecular mechanisms
which regulate lymphangiogenesis is still required.
Conclusions
The present study demonstrated that VEGF-C/D ex-
pression were significantly higher in breast cancer. The
expression of these factors was significantly associated
with peritumoral LVD, but not intratumoral LVD. And
peritumoral LVD was significantly associated with
lymph node metastasis, lymphatic vessel invasion and
late TNM stage. However no such relationship was
found with intratumoral LVD. Moreover, peritumoral
LVD was an independent risk factor for axillary lymph
node metastasis, overall survival and disease-free sur-
vival. Inhibiting the expression of VEGF-C/D to control
peritumoral lymphangiogenesis is expected to lead to
the development of novel therapeutic strategies for
breast cancer.
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